ALT — Altimmune, Inc.

Altimmune Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of April 30, 2026, Altimmune reported a cash balance of approximately $535 million, following an oversubscribed public offering that generated $225 million in gross proceeds.
• R&D Expenses: Q1 2026 R&D expenses totaled $16.2 million, slightly up from $15.8 million in Q1 2025, primarily due to ongoing trials for Alcohol Use Disorder (AUD) and Alcoholic Liver Disease (ALD).
• G&A Expenses: General and administrative expenses rose to $8.1 million from $6 million year-over-year, driven by increased severance costs and professional fees.
• Net Loss: The net loss for Q1 2026 was $22.6 million, or $0.18 per share, compared to a net loss of $19.6 million, or $0.26 per share, in the same quarter of 2025.

2. Strategic Updates and Business Highlights

• Pemvidutide Development: Altimmune is advancing its lead candidate, pemvidutide, for the treatment of Metabolic Dysfunction Associated Steatotic Liver Disease (MASH). The company is preparing to initiate the Phase III PERFORMA trial in the second half of 2026.
• Regulatory Designations: Pemvidutide has received Breakthrough Therapy Designation from the FDA for MASH, highlighting its potential in a market with significant unmet needs.
• Clinical Trials: The company is on track to report top-line data from the Phase II trial for AUD in Q3 2026 and expects to complete enrollment for the RESTORE trial in ALD by Q3 2026.
• Market Research: Recent studies indicate a favorable tolerability profile for pemvidutide, which is expected to drive physician prescribing in the evolving MASH market.

3. Forward Guidance and Outlook

• Phase III Trial: The initiation of the PERFORMA Phase III trial is anticipated in the second half of 2026, with a focus on executing the trial effectively.
• Data Readouts: Top-line data from the Phase II AUD trial is expected in Q3 2026, which will inform future investment decisions regarding the AUD program.
• Long-Term Strategy: Altimmune aims to leverage its strong cash position to advance pemvidutide through late-stage development and regulatory submissions, targeting significant market opportunities in liver diseases.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Rising R&D and G&A expenses may pressure profitability, although they are aligned with ongoing clinical development efforts.
• Market Competition: The increasing number of competing therapies, including triple agonists, poses a risk to pemvidutide’s market positioning. The company must demonstrate clear differentiators to maintain competitive advantage.
• Regulatory Risks: The success of the Phase III trial and subsequent regulatory approvals remain uncertain, with potential challenges in meeting endpoints.

5. Notable Q&A Insights

• EASL Presentations: Upcoming presentations at the EASL conference will showcase new data on fibrosis regression and weight loss, which are critical for pemvidutide's profile.
• Interim Analysis: The Phase III MASH trial is designed as an event-driven study with a 52-week biopsy endpoint, but no interim analyses are planned beyond this.
• Differentiation from Competitors: Management emphasized pemvidutide's unique 1:1 glucagon-GLP-1 ratio and favorable tolerability profile as key differentiators from other therapies, particularly in the context of chronic liver diseases.
• Patient Adherence: High adherence rates observed in Phase II trials are expected to be a significant advantage in chronic disease management, which could enhance pemvidutide's market acceptance.

Overall, Altimmune is positioned for significant advancements in its clinical programs, supported by a robust financial foundation, while navigating competitive and regulatory challenges in the evolving liver disease market.